Skip to main content
. Author manuscript; available in PMC: 2024 Mar 15.
Published in final edited form as: J Invest Dermatol. 2017 Oct 24;138(2):434–443. doi: 10.1016/j.jid.2017.09.030

Figure 1. Wound closure measurements in mice treated with different angiotensin system blockers at different time points of wound healing.

Figure 1.

Planimetric assessment of (a) the wound closure rate and biomechanical assessment, n = 6 mice per group, and of (b) healed skin in diabetic (Leprdb/J) mice treated with 5% topical losartan, n = 3–5 mice per group. (c) Laser Doppler perfusion imaging of wound area blood flow, n = 5 mice per group. (d) Planimetric assessment of the wound closure rate in Leprdb/J mice treated with different doses of valsartan and losartan gels applied 7 days after wounding, n = 7–8 mice per group. (e) Altered mRNA expression of wound angiotensin receptors and TGFβ isoforms in Leprdb/J mice treated with losartan 1% and valsartan 1%, n = 3–5 mice per group. (f) Kaplan-Meier analysis of complete wound closure in Leprdb/J mice treated with 1% valsartan n = 7–8 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, +++P < 0.001 los 1% versus val 1% early stage, +P < 0.05 los 1% versus val 1% late stage of wound healing. AT1R, angiotensin II type 1 receptor; TGFβ, transforming growth factor-beta.